Restricted accessResearch articleFirst published online 1987-10
Effect of Transfer of Erythrocytes to a Nonuremic Medium on Corpuscular Parameters and Red Blood Cell Deformability in Patients Treated with CAPD and Hemodialysis
We studied the effect produced on corpuscular parameters and erythrocyte deformability by transfer of red blood cells to a nontoxic isoosmotic medium. The study groups were uremic patients treated with hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD). Erythrocyte deformability was estimated by the erythrocyte filtration rate (EFR). Transfer resulted in a significant decrease in mean corpuscular volume (MCV) and an increase in mean corpuscular hemoglobin concentration (MCHC), in comparison with healthy controls. The principal cause for this may be an improvement in erythrotycte membrane function. The change was more marked in the CAPD than in the HD patients; CAPD patients displayed a clear tendency to microcytosis after changing media, not directly attributable to iron deficiency or aluminum intoxication. Erythrocyte deformability was decreased markedly in all the patients, but study of the EFR of washed erythrocytes suggested that there was more impairment in HD. These differences could have some effect on the response of the hemolytic component of the anemia of uremia to HD and CAPD.
EschbachJ.W.Hematologic problems in dialysis patients. In; DrukkerW. eds. Replacement of renal function by dialysis.Nijhoff Publishing: Boston. 1983; 630–645.
2.
AnagostouA.A., FriedW.The hemopoietic system. In: EknoyanG. eds. The systemic consequences of renal failure.Grune & Stratton: Orland. 1983; 331–365.
3.
DesforgesJ.F.Anemia in uremia.Arch Intern Med1970; 126: 808–811.
4.
FisherJ.W.Mechanism of the anemia of chronic renal failure.Nephron1980; 25: 106–111.
5.
KinseyE., SmithM., WeltL.G.The red blood cell as a model for the study of uremic toxin.Arch Intern Med1970; 126: 827–830.
6.
ZannadF., KesslerM., RoyerR.J.Effect of hemodialysis on red blood cell Na-K-ATPase activity in terminal renal failure.Nephron1985; 40: 127–128.
7.
KramerH.J., GospodinovD., KruckF.Functional and metabolic studies on red blood cell sodium transport in chronic uremia.Nephron1976; 16: 344–358.
8.
ZannadF., RoyerR.J., KesslerM.Cation transport in erythrocytes of patients with chronic renal failure.Nephron1982; 32: 347–350.
9.
FrancavillaA., AlbanoO., MastrangeloF.Erythrocyte membrane A TPase in patients with acute or chronic renal disease.Clin Chim Acta1972; 37: 298–300.
10.
YawataY., JacobH.S.Abnormal red cell metabolism in patients with chronic uremia: Nature of the defect and its persistence despite adequate hemodialysis.Blood1975; 45: 231–239.
DiezJ., AitizabalagaB., FemandexJ.Estudio electroforetico de las proteinas de la membrana eritrocitaria en pacientes en hemodialisis cronica.Nefrologia1982; 2: 7–11.
HockenA.G.Hemolysis in chronic renal failure.Nephron1982; 32: 28–31.
18.
KhannaR., OreopoulosD.O.Complications of peritoneal dialysis other than peritonitis. In: NolphK.D. ed. Peritoneal dialysis.Martinus Nijhoff: Boston; 1985: 441–524.
19.
HeftiJ.E., BlumbergE., MartiH.R.Red cell survival and red cell enzymes in patients on CAPD.Clin Nephrol1983; 19; 232–235.
20.
Shainkin-KestenbaumR., OiatR., BeriyneO.M.The toxicity of guanidino compounds in the red blood cell in uremia and the effects of hemodialysis.Nephron1982; 31: 20–23.
21.
PotasmanI., BetterO.S.The role of secondary hyperparathyroidism in the anemia of chronic renal failure.Nephron1983; 33: 229–231.
22.
MassryS.O.Pathogenesis of the anemia of uremia; role of secondary hyperparathyroidism.Kidney Int1983; 24: 204–207.
23.
DocciD., TurciF., BaldratiL.Lack of relation between secondary hyperparathyroidism and red blood cell osmotic fragility in chronic renal failure.Nephron1985; 41: 241–245.
24.
DocciD., Del VecchioC., SalviPOsmotic fragility of erythrocytes, cell deformability and secondary hyperparathyroidism in uremic patients on maintenance hemodialysis.Clin Nephrol1985; 23: 68–73.
25.
GoldC.H., ViljoenM., MzamaneDV A.The lack of effect of guanidinoacetic acid on in vitro osmotic fragility of erythrocytes.Nephron1982; 31: 17–19.
26.
DesforgesJ.F.The role of hemodialysis in the hematological disorders of uremia.Kidney Int1975; 7: 123–128.
27.
SantiagoO.C., Sreepada RaoT.K., LairdN.M.Effect of dialysis therapy on hematopoietic system: The national cooperative dialysis study.Kidney Int1983; 23: 95–100.
28.
SpinowitzB.S., SherwoodJ., OallerM.Anemia and oxygen affinity in patients on CAPD.Perit Dial Bull1983; 3: S33–35.
29.
DePaepeM.B.J., ScheelstraeteK.H.G., RingoirS.M.G.Influence of CAPD on the anemia of end stage renal disease.Kidney Int1983; 23: 744–748.
30.
SaltissiD., ColesG.A., NapierJ.A.F.The hematological response to CAPD.Clin Nephrol1984; 22: 21–27.
ReidH.L., DormandyJ.A., BarnesA.J.Impaired red cell deformability in peripheral vascular disease.Lancet1976; i: 666–668.
33.
EsterA., VivesJ.L., BergaL.Estudio de la deformabilidad eritrocitaria mediante filtracion.Sangre1982; 27: 8620871.
34.
SprietA., BeilerD., GrumelJ.A.Etude multicentrique sur les facteurs extra-erythrocytaires de la filtration: Resultats preliminaires. IV Seminaire du Group de Travail sur la filtration erythrocytaire. September 13–15, 1979; 49–65.
